E210 - The PsychopharmaStahlogy Show: Potenti...

In this episode, Dr. Andy Cutler talks with Dr. Robert Cotes about optimizing outcomes in early psychosis and why the first episode is a critical window for intervention. They discuss the impact of duration of untreated psychosis, recovery trajectories after a first episode, and ...  Show more

PsychopharmaPearls is NEI's focused podcast series highlighting the clinical insights that can sharpen your prescribing decisions. In this episode, Dr. Andy Cutler talks with Dr. Lisa Harding about how to choose between IV ketamine and intranasal esketamine for patients with diff ...  Show more

Send a textThe path to FDA approved prescribable medicine has been a long and precarious one for psychedelics. However, recent reports by some of the major players in the psychedelic medicine space show promising results from clinical trials involving psilocybin and 5-MeO-DMT. In ...  Show more

In this Huberman Lab Essentials episode, my guest is Dr. Matthew Johnson, PhD, a senior researcher for the Center of Excellence for Psilocybin Research and Treatment at Sheppard Pratt’s Institute for Advanced Diagnostics and Therapeutics. We explore the science and therapeutic po ...  Show more

In this episode, Joe interviews Josh Lipson, a Ph.D. candidate in clinical psychology at Columbia University, whose research explores the relationship between psychedelics, mystical experiences, and mental health. He discusses the complexities of studying psychedelics in real-wor ...  Show more

Send a textIn this episode of the Psychedelic Therapy Frontiers podcast Dr. Steve Thayer and Dr. Reid Robison explore how psychedelic experiences might solicit false or maladaptive beliefs. Learn more about our podcast at https://numinusnetwork.com/learn/podcast/Learn more about ...  Show more